Results for Cancer Therapy

1 - 10 of 368

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

E-mail:

weberew [at] chop.edu

Aime T. Franco, PhD

Dr. Franco researches the molecular basis of the differences between pediatric and adult onset thyroid cancer. She aims to understand how the tumor microenvironment impacts disease progression and response to therapy.

E-mail:

francoa1 [at] chop.edu

David M. Barrett, MD, PhD

Dr. Barret's research program focuses on immune function of children with cancer. His research involves investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.

E-mail:

barrettd [at] chop.edu

Stephen P. Hunger, MD

Dr. Hunger's focuses his research on molecular and genomic approaches to identify and clinically evaluate targeted cancer treatments for children with relapsed or high-risk acute lymphoblastic leukemia (ALL) such as Philadelphia chromosome-like (Ph-Like) ALL. The long-term goal of Dr. Hunger’s research is to develop better therapies, improve cure rates, and minimize treatment toxicities for children with ALL.

E-mail:

hungers [at] chop.edu

Leyuan Ma, PhD

Dr. Ma focuses on immune engineering. He leverages genetic, chemistry, and engineering tools to dissect immune cell-cell and cell-tissue crosstalk and harness these crosstalk mechanisms to develop biomaterials, protein, and cell-based precision immunotherapies for cancer and autoimmune diseases.

E-mail:

mal5 [at] chop.edu

Sogol Mostoufi-Moab, MD, MSCE

Dr. Mostoufi-Moab's clinical and research program is focused on endocrine late effects after childhood cancer therapy. She has unique dual training in pediatric endocrinology and oncology with a master's degree in clinical epidemiology. The goal of her research program is to pursue a mechanistic understanding of metabolic and endocrine disorders that occur due to cancer therapy.

E-mail:

moab [at] chop.edu

John M. Maris, MD

Dr. Maris investigates the molecular and genetic mechanisms contributing to the development and progression of neuroblastoma, a common childhood cancer. He also aims to develop new molecular diagnostic tests and less toxic, targeted therapies to treat relapsed or refractory neuroblastoma, including a major effort in immunotherapy discovery and development.

E-mail:

maris [at] chop.edu

Garrett M. Brodeur, MD

Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.

E-mail:

brodeur [at] chop.edu

Richard Aplenc, MD, PhD, MSCE

Dr. Aplenc investigates ways to improve the outcomes of children with cancer, particularly acute myeloid leukemia, with clinical epidemiology studies and translational research.

E-mail:

aplenc [at] chop.edu

Theodore Laetsch, MD

Dr. Laetsch is a pediatric oncologist who provides clinical care and conducts research with the overarching goal of improving treatment options for children with difficult to treat cancers.

E-mail:

laetscht [at] chop.edu